About Evotec
Evotec is a publicly listed company based in Hamburg (Germany) founded in 1993. It operates as a drug discovery and development services are provided to biopharma sector. Evotec has raised $25 million across 22 funding rounds from investors including Gates Foundation, Mubadala and 3i Group. The company has 4,830 employees. Evotec has completed 11 acquisitions, including Aptuit, CG Germany and CGC Japan. Its website evotec.com draws about 91 thousand monthly visits. Evotec offers products and services including PanOmics Platform, CRO/CDMO Services, and iPSC Technologies. Its focus areas include Biopharma Outsourcing, CRO and Drug Discovery. Its legal entity in India is Evotec (India) Private Limited (U74130MH2004PTC145141). Its competitors include Crown Bioscience, Alloy Therapeutics, Domainex, NIH and Viva Biotech and 4 more; 6 of its 9 listed competitors have raised funding.
Company details
Evotec was founded in 1993 in Hamburg, Germany, as a provider of drug discovery alliance and development services. Operations focus on supporting the biopharma industry through integrated solutions for target identification, screening, and preclinical advancement. Services encompass chemistry, biology, and informatics platforms, with global collaborations extending beyond Europe to facilitate efficient RD pipelines for pharmaceutical partners.
- Headquarters Hamburg, Germany
- Employees 4,830
- Stage Public
- SectorsHealthcare
- Website evotec.com
- Social LinkedIn X
- Legal Name Evotec Se
- Annual Revenue$926.33 M (USD)-1.08as on Dec 31, 2025
- Net Profit-$121.64 M (USD)47.21as on Dec 31, 2025
- EBITDA-$48.65 M (USD)40.37as on Dec 31, 2025
- Total Equity Funding$25M (USD)
in 22 rounds
- InvestorsGates Foundation
& 14 more
- Employee Count4,830
- Investments & AcquisitionsAptuit
& 10 more
Associated legal entities of Evotec
Evotec operates through Evotec (India) Private Limited (under liquidation). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Evotec (India) Private Limited CIN U74130MH2004PTC145141 | Under Liquidation | 17 Mar 2004 | Mumbai, Maharashtra | – | – | 3 | View details |
Products & Services of Evotec
Evotec offers a comprehensive portfolio of products and services, including PanOmics Platform, CRO/CDMO Services, and iPSC Technologies.
AI-powered platform for analyzing disease data and advancing research.
Services for efficient drug development from concept to clinical stages.
Tools for human-relevant disease modeling and therapeutic testing.
Funding Insights of Evotec
Evotec has successfully raised a total of $25M across 22 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25M
- Total Rounds 22
- First Round $25M
(Mar 1998)
- Investors Count 15
Latest 10 of 22 funding rounds of Evotec with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | – | Grant | – | – | |
| May 2025 | $2.5M | Grant | – | – | |
| Jun 2023 | $1.7M | Grant | – | – | |
| Mar 2023 | $6.6M | Grant | – | – | |
| Jan 2022 | $8.3M | Grant | – | – | |
| Oct 2020 | – | Grant | – | – | |
| Oct 2020 | $295.27M | Post-IPO | – | – | |
| Aug 2020 | – | Grant | – | – | |
| Oct 2019 | $97,473 | Grant | – | – | |
| Jan 2019 | $2M | Grant | – | – |
15 investors in total: 15 institutional.
Investors in Evotec
Evotec has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Mubadala and 3i Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | – | novoholdings.dk | Hellerup, Denmark | |
Private equity firm focused on mid-market businesses | 1945 | 3i.com | London, United Kingdom | |
Private equity investments in healthcare companies are managed. | 1997 | mvm.com | London, United Kingdom | |
Early-stage funding is provided to innovative founders by Ventech. | – | ventechvc.com | Paris, France | |
Early & late stage sector-agnostic VC firm investing in the US, Asia and Middle East | – | star-ventures.com | Herzliya, Israel | |
Open Philanthropy is engaged in funding impactful global initiatives. | – | openphilanthropy.org | San Francisco, United States | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Education and research policies are overseen by the ministry. | 1955 | bmbf.de | Berlin, Germany | |
Sovereign wealth fund of United Arab Emirates | 2002 | mubadala.com | Abu Dhabi, United Arab Emirates | |
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed. | 2016 | carb-x.org | Boston, United States |
Investor details for Evotec
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Evotec (India) Private Limited (Evotec)
Evotec (India) Private Limited is the primary company behind Evotec. The board of Evotec (India) Private Limited currently have 3 directors; the longest-serving is Mario Polywka, appointed in 2009. 15 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mario Polywka DIN 01750310 | Director | 31 Aug 2009 | 17 yrs 1 mo | Evotec (India) Private Limited |
| Colin Michael Bond DIN 03479234 | Director appointed in casual vacancy | 14 Oct 2010 | 16 yrs | Evotec (India) Private Limited |
| David John DIN 00204851 | Director | 05 Oct 2011 | 15 yrs | Evotec (India) Private Limited |
People of Evotec
425 people are tracked at Evotec (109 in leadership, 5 in board & advisors, 311 in team); the tracked headcount is 4,830.
| Name | Role | Group |
|---|---|---|
Francesca Altieri | SVP Head Of Talent Management & Organizational Development | Leadership |
Yvonne Hansen | HR Business Partner | Leadership |
Federica Ferigo | Svp, Head Of Business Intelligence & Operations, Partnering Excellence & Operations | Leadership |
Sarah Gouzy | Human Resources Business Partner | Leadership |
Judith Hansen | VP Strategic HR Projects | Leadership |
Irving Donadon | Director, Global Business Development, Cell Therapy | Leadership |
Stephan Pinto Spindler | VP Head Of Cyber Security | Leadership |
Gregory Vert | VP Protein Homeostasis | Leadership |
Samara Collins | Head Of Human Resources | Leadership |
Marco Pergher | Vp, Head Of Pharmacometrics | Leadership |
Sven Sauer | VP Computational Biology | Leadership |
Marcel van Gaalen | Vice President, Translational Sciences – New Technologies; In Vivo Global Data Lead | Leadership |
Eric Cogo | Vp, DMPK And Developability Assessment - Evotec France | Leadership |
Marie Monsigna | HR Site Head | Leadership |
Julia Marie MacHinek | Vice President, Head Of Legal, Drug Discovery | Leadership |
Kamran Bashir | VP Head Of Finance (uk) | Leadership |
Amanda Giddings | VP Head Of Project Toxicology And Discovery Safety | Leadership |
Flavia Cottini | Senior Vice President Finance | Leadership |
Nadia Stagg | Head Of UK Accounting | Leadership |
Franck Lepifre | VP Head Of Chemistry | Leadership |
405 more people are available in the full profile.
Complete people profiles for Evotec
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Evotec
Evotec is a publicly listed company on the XETR with ticker symbol EVT in Germany, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Nov 2021
- Listed onNASDAQ: EVO
- Listed entityEvotec SE
- Exchange sectorHealth technology
- ISINDE0005664809
- Share price2.61 EUR (+6.87% on the day) · 2026-10-14
- Market capitalisation434,201,162.00 EUR
- EPS (diluted, trailing year)-1.11 EUR
- Volume (last session)774,226
Financials of Evotec
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 788.4M EUR | -103.5M EUR | -41.4M EUR |
| 2024 | 797.0M EUR | -196.1M EUR | -69.4M EUR |
| 2023 | 781.4M EUR | -83.9M EUR | -7.2M EUR |
| 2022 | 751.5M EUR | -175.7M EUR | 13.0M EUR |
| 2021 | 618.0M EUR | 215.5M EUR | 33.7M EUR |
Balance sheet, profit and loss, cash flow and ratios of Evotec (India) Private Limited are on its company page.
Detailed financial statements for Evotec
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evotec
Evotec has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include Aptuit, CG Germany and CGC Japan.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Chemical research, production, and development services are provided. | cg-germany.com | Halle, Germany | 2008 | Aug 2022 | •••• | |
Specialized glasses are manufactured and supplied for multiple industries. | cgc-jp.com | Chiyoda, Japan | 1936 | Aug 2022 | •••• | |
Developer and producer of cGMP products for cell-gene therapy | rigenerand-biotech.com | Medolla, Italy | 2009 | May 2022 | $24.68M | |
Designing technologies to accelerate biotherapeutic development and to reduce manufacturing costs | justbiotherapeutics.com | Seattle, United States | 2014 | May 2019 | •••• | |
Contract research and development services for small molecules are offered. | aptuit.com | Greenwich, United States | 2004 | Jul 2017 | $300M | |
Predictive toxicology and in vitro and in silico ADME services provider | cyprotex.com | Macclesfield, United Kingdom | 1999 | Oct 2016 | $70.53M | |
Preclinical services for anti-infective drugs are provided. | euprotec.com | Manchester, United Kingdom | 2008 | May 2014 | $3.2M | |
Chemical proteomics for cellular target profiling and drug discovery services | kinaxo.de | Saarwellingen, Germany | 2005 | Feb 2011 | $21.8M | |
Novel therapeutics are discovered for metabolic and endocrine disorders. | develogen.com | Gottingen, Germany | 1996 | Jul 2010 | $17.68M | |
Drugs for neurological diseases are discovered and developed. | renovis.com | San Francisco, United States | 2000 | Sep 2007 | •••• |
Complete acquisition details for Evotec
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Evotec
14 dated milestones of Evotec across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Evotec is founded.
- Funding First funding round of $25.0M.
- Acquisition Acquires Renovis.
- Acquisition Acquires DeveloGen.
- Acquisition Acquires Kinaxo Biotechnologies.
- Acquisition Acquires Euprotec.
- Acquisition Acquires Cyprotex.
- Acquisition Acquires Aptuit.
- Acquisition Acquires Just Biotherapeutics.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Rigenerand.
- Acquisition Acquires CGC Japan.
- Acquisition Acquires CG Germany.
- Funding Latest funding round, Grant,.
Competitors of Evotec
Evotec has 9 listed competitors in our database, 6 of them funded. They include Crown Bioscience, Alloy Therapeutics, Domainex, NIH and Viva Biotech, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| crownbio.com | 2006 | Santa Clara, United States | $85.87M | 18 | Cancer and CVMD drugs are developed using PDX models. | |
| alloytx.com | 2017 | Lexington, United States | $157M | – | Drug discovery services are provided for therapeutic development. | |
| domainex.co.uk | 2001 | Cambridge, United Kingdom | $4.97M | 93 | Drug discovery CRO company for epigenetic research and inflammatory diseases | |
| nih.gov | 1887 | United States | – | – | Drug discovery services are provided to the biopharma sector. | |
| vivabiotech.com | 2006 | Shanghai, China | – | – | Drug discovery and development research services are provided. | |
| catsci.com | 2010 | Cardiff, United Kingdom | $5.89M | 63 | Drug discovery services are provided to pharmaceutical clients worldwide. | |
| qyuns.net | 2015 | Taizhou, China | $66.35M | – | Drug development services are provided to the biopharma sector. | |
| conceptlifesciences.com | 2014 | Manchester, United Kingdom | – | – | International laboratory testing and consultancy in life sciences are offered. | |
| staqpharma.com | 2018 | Denver, United States | $33.52M | 30 | Drug discovery services are provided for pharmaceutical innovation. |
Detailed competitors of Evotec
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Evotec
The website of Evotec (evotec.com) receives about 91K visits a month.
- Monthly visits91K
▲ 6.8% vs previous month
Websites whose visitors overlap most with Evotec. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| criver.com | 100% | 224.6K | #186,811 | View details | |
bioprocessintl.com | bioprocessintl.com | 92% | – | #504,676 | – |
| bioivt.com | 92% | 78.2K | #447,808 | View details | |
| cyrusbio.com | 92% | 1.9K | #9,105,938 | View details | |
| parsebiosciences.com | 92% | 62.7K | #493,988 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Evotec
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
10 companies that operate in the same segment as Evotec (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 | |
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure | 2013 | Lexington, Kentucky, United States | USD 78.75 M | USD 36.33 M | 164 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Evotec
Complete news archive for Evotec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evotec
Evotec was founded in 1993 and raised its 1st funding round 5 years after it was founded.
Evotec is headquartered in Hamburg, Germany. It is registered at Hamburg, Hamburg, Germany.
Evotec is a funded company, having raised a total of $25M across 22 funding rounds to date. The company's 1st funding round was a Grant of $2M, raised on Mar 1998.
Evotec has 4,830 employees.
Annual revenue of Evotec is $926.33M as on Dec 31, 2025.
Evotec was founded in 1993 in Hamburg, Germany, as a provider of drug discovery alliance and development services. Operations focus on supporting the biopharma industry through integrated solutions for target identification, screening, and preclinical advancement. Services encompass chemistry, biology, and informatics platforms, with global collaborations extending beyond Europe to facilitate efficient RD pipelines for pharmaceutical partners.
Evotec's top competitors include Crown Bioscience, NIH and Domainex.
Evotec offers PanOmics Platform, CRO/CDMO Services, and iPSC Technologies.
Yes, Evotec is publicly traded on XETR under the ticker symbol EVT.
Evotec has made 11 acquisitions, including Aptuit, CG Germany, and CGC Japan.
Evotec has 15 investors. Key investors include Gates Foundation, Mubadala, 3i Group, CARB-X, and European Union.
Evotec operates through Evotec (India) Private Limited.